Sol-Gel Technologies Announces Management Realignment
July 15, 2024 07:00 ET
|
Sol-Gel Technologies Ltd.
Sol-Gel Technologies Announces Management Realignment
PSYC Provides Shareholders with Key Corporate Updates and Highlights Objectives for 2023
January 31, 2023 08:30 ET
|
PSYC Corporation
LAS VEGAS, NV, Jan. 31, 2023 (GLOBE NEWSWIRE) -- PSYC Corporation (OTC Pink Market: PSYC) (“PSYC”, “PSYC Corp” or the “Company”), parent company to Spotlight Media Corporation (“SMC” or the “wholly...
Bell Buckle Holdings, Inc. Updates Shareholders and Enters into Discussions with Two Operating Companies
February 17, 2022 15:15 ET
|
Bell Buckle Holdings, Inc.
Naples, FL, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Bell Buckle Holdings Inc. (OTC Pink: BLLB) (“The Company”) is pleased to update shareholders on our progress in 2022 and continues to execute on our...
Bell Buckle Holdings Confirms Removal of Caveat Emptor Designation and Provides Corporate Updates
January 25, 2022 06:00 ET
|
Bell Buckle Holdings, Inc.
Naples, FL, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Bell Buckle Holdings Inc. (OTC Pink: BLLB) (“The Company”) is pleased to announce that the Caveat Emptor Designation has been removed and the Company is...
Vemanti Group Announces Corporate Updates and Developments
July 01, 2020 08:30 ET
|
Vemanti Group, Inc
IRVINE, Calif., July 01, 2020 (GLOBE NEWSWIRE) -- Vemanti Group, Inc. (OTC PINK:VMNT) a multi-asset technology-driven company, today provided its corporate updates and developments. The Company’s Q2...
Corbus Pharmaceuticals Reports First Quarter Financial Results and Corporate Updates
May 11, 2020 07:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Topline results for lenabasum Phase 3 RESOLVE-1 study in systemic sclerosis remain on schedule for summer of 2020, followed by Phase 2b study data in cystic fibrosis Phase 1 trial of CRB-4001 remains...
Corbus Pharmaceuticals Reports 2019 Third Quarter Financial Results and Provides Clinical and Corporate Updates
November 07, 2019 07:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Phase 3 “RESOLVE-1” study of lenabasum for treatment of systemic sclerosis on track for topline results in summer of 2020Systemic sclerosis is a rare autoimmune disease affecting ~200,000 people in...
Bullfrog Gold Receives Nevada Permits and Provides Corporate and Project Updates
July 15, 2019 06:00 ET
|
Bullfrog Gold Corp
GRAND JUNCTION, Colo., July 15, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Bullfrog Gold Corp (OTCQB: BFGC) (“BFGC” or the “Company”) is pleased to announce issuance of environmental permits and...
Vitality Biopharma Announces Corporate Updates and Completion of an SEC Examination
November 21, 2018 07:00 ET
|
Vitality Biopharma, Inc
Company appoints two new directors including the Hon. Edward Feighan as new Chairman of the Board LOS ANGELES, Nov. 21, 2018 (GLOBE NEWSWIRE) -- Vitality Biopharma, Inc. (OTCQB: VBIO)...